 <safetyreport>
 <safetyreportversion>1</safetyreportversion>
 <safetyreportid>TR-XXXXXXXXX-2014GMK012399</safetyreportid> 
<primarysourcecountry>TR</primarysourcecountry>
 <occurcountry>TR</occurcountry>
 <transmissiondateformat>102</transmissiondateformat>
 <transmissiondate>20231122</transmissiondate>
 <reporttype>1</reporttype>
 <serious>1</serious>
 <seriousnessdeath>2</seriousnessdeath>
 <seriousnesslifethreatening>2</seriousnesslifethreatening>
 <seriousnesshospitalization>2</seriousnesshospitalization>
 <seriousnessdisabling>2</seriousnessdisabling>
 <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
 <seriousnessother>1</seriousnessother>
 <receivedateformat>102</receivedateformat>
 <receivedate>20141115</receivedate>
 <receiptdateformat>102</receiptdateformat>
 <receiptdate>20141115</receiptdate>
 <additionaldocument>1</additionaldocument>
 <documentlist>Source Documents</documentlist>
 <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
 <companynumb>TR-XXXXXXXXX-2014GMK012399</companynumb>
 <fdasafetyreporttype>3</fdasafetyreporttype>
 <primarysource>
<reportergivename>D</reportergivename>
<reporterfamilyname>Aksoy</reporterfamilyname>
<reporterorganization>Gaziosmanpasa University</reporterorganization>
<reporterdepartment>Department Of Neurology</reporterdepartment>
<reporterstreet>Faculty of Medicine,
Muhittin Fusunoglu cd.</reporterstreet>
<reportercity>Tokat</reportercity>
<reporterpostcode>60100</reporterpostcode>
<reportercountry>TR</reportercountry>
<qualification>3</qualification>
<literaturereference>Aksoy D, Cevik B, Kurt S, Pekdas E, Solmaz V. Hypokalemia and hypomagnesaemia 
related to levetiracetam use. J Clin Neurosci.. 2014;S0967-5868(14):00220-3</literaturereference>
 </primarysource>
 <sender>
<sendertype>1</sendertype>
<senderorganization>GMARK</senderorganization>
<senderstreetaddress>XXXXXXXXX Inc, USA. 750 Corporate 
Drive</senderstreetaddress>
<sendercity>Mahwah</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>07430</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>2016848000</sendertel>
<senderemailaddress>Drugsafety@glenmarkpharma.com</senderemailaddress>
 </sender>
 <receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
<receivertitle>Mr.</receivertitle>
<receivergivename>Roger</receivergivename>
<receiverfamilyname>Goetsch</receiverfamilyname>
<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
<receivercity>Landover</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20785</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>2404877373</receivertel>
<receivertelcountrycode>001</receivertelcountrycode>
<receiverfax>3019183134</receiverfax>
<receiverfaxcountrycode>001</receiverfaxcountrycode>
<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
 </receiver>
 <patient>
<patientinitial>UNKNOWN</patientinitial>
<patientonsetage>23</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientsex>1</patientsex>
<resultstestsprocedures>Hypokalemia (3.1mmol/L) 
Hypomagnesaemia (0.56mmol/L)
Hemogram, Blood urea nitrogen, Creatinine, Total cortisol, Thyroid function tests, Creatinine clearance,
and Renal Doppler ultrasound were normal</resultstestsprocedures>
<medicalhistoryepisode>
<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
<patientepisodename>Convulsion</patientepisodename>
<patientmedicalcontinue>2</patientmedicalcontinue>
</medicalhistoryepisode>
<patientpastdrugtherapy>
<patientdrugname>VALPROATE</patientdrugname>
</patientpastdrugtherapy>
<reaction>
<primarysourcereaction>Renal tubular disorder</primarysourcereaction>
<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
<reactionmeddrallt>Renal tubular disorder</reactionmeddrallt>
<reactionmeddraversionpt>17.1</reactionmeddraversionpt>
<reactionmeddrapt>Renal tubular disorder</reactionmeddrapt>
<reactionoutcome>6</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>Interstitial nephritis</primarysourcereaction>
<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
<reactionmeddrallt>Tubulointerstitial nephritis</reactionmeddrallt>
<reactionmeddraversionpt>17.1</reactionmeddraversionpt>
<reactionmeddrapt>Tubulointerstitial nephritis</reactionmeddrapt>
<reactionoutcome>6</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>Renal failure</primarysourcereaction>
<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
<reactionmeddrallt>Renal failure</reactionmeddrallt>
<reactionmeddraversionpt>17.1</reactionmeddraversionpt>
<reactionmeddrapt>Renal failure</reactionmeddrapt>
<reactionoutcome>6</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>Hypokalemia</primarysourcereaction>
<reactionmeddraversionllt>17.0</reactionmeddraversionllt>
<reactionmeddrallt>Hypokalemia</reactionmeddrallt>
<reactionmeddraversionpt>17.0</reactionmeddraversionpt>
<reactionmeddrapt>Hypokalaemia</reactionmeddrapt>
<reactionoutcome>6</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>Hypomagnesaemia</primarysourcereaction>
<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
<reactionmeddrallt>Hypomagnesaemia</reactionmeddrallt>
<reactionmeddraversionpt>17.1</reactionmeddraversionpt>
<reactionmeddrapt>Hypomagnesaemia</reactionmeddrapt>
<reactionoutcome>6</reactionoutcome>
</reaction>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>Levetiracetam</medicinalproduct>
<obtaindrugcountry>UK</obtaindrugcountry>
<drugauthorizationnumb>078234</drugauthorizationnumb>
<drugauthorizationcountry>US</drugauthorizationcountry>
<drugauthorizationholder>XXXXXXXXX Inc.</drugauthorizationholder>
<drugdosagetext>UNK</drugdosagetext>
<drugdosageform>Unknown</drugdosageform>
<drugindicationmeddraversion>18.0</drugindicationmeddraversion>
<drugindication>Seizure</drugindication>
<actiondrug>1</actiondrug>
<activesubstance>
<activesubstancename>LEVETIRACETAM</activesubstancename>
</activesubstance>
<drugreactionrelatedness>
<drugreactionassesmeddraversion>17.0</drugreactionassesmeddraversion>
<drugreactionasses>Hypokalaemia</drugreactionasses>
<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
<drugassessmentmethod>Global Introspection</drugassessmentmethod>
<drugresult>Yes</drugresult>
</drugreactionrelatedness>
<drugreactionrelatedness>
<drugreactionassesmeddraversion>17.0</drugreactionassesmeddraversion>
<drugreactionasses>Hypokalaemia</drugreactionasses>
<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
<drugassessmentmethod>Global Introspection</drugassessmentmethod>
<drugresult>Yes</drugresult>
</drugreactionrelatedness>
<drugreactionrelatedness>
<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
<drugreactionasses>Hypomagnesaemia</drugreactionasses>
 <drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Hypomagnesaemia</drugreactionasses>
 <drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Renal failure</drugreactionasses>
 <drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Renal failure</drugreactionasses>
 <drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Renal tubular disorder</drugreactionasses>
 <drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Renal tubular disorder</drugreactionasses>
 <drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Tubulointerstitial nephritis</drugreactionasses>
 <drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 <drugreactionrelatedness>
 <drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
 <drugreactionasses>Tubulointerstitial nephritis</drugreactionasses>
 <drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
 <drugassessmentmethod>Global Introspection</drugassessmentmethod>
 <drugresult>Yes</drugresult>
 </drugreactionrelatedness>
 </drug>
 <summary>
 <narrativeincludeclinical>2014GMK012399/(TR): This is literature case report received on 15-Nov-2014 
derived from scientific literature published by Aksoy D, Cevik B, Kurt S et al., pertaining to 23-year-old 
male patient who developed renal tubular disorder (RENAL TUBULAR DISORDER) associated with interstinal 
nephritis (TUBULOINTERSTITIAL NEPHRITIS), renal failure (RENAL FAILURE), hypokalemia (HYPOKALEMIA) and 
hypomagnesaemia (HYPOMAGNESAEMIA) while receiving levetiracetam (strength, formulation and manufacturer 
unknown) for seizures. 
Citation: Aksoy D, Cevik B, Kurt S, Pekdas E, Solmaz V. Hypokalemia and hypomagnesaemia related to 
levetiracetam use. J Clin Neurosci.2014; S0967-5868(14):00220-3.
Past drug of patient included valproate. Concomitant medications were unknown at the time of report. 
On an unknown date, patient was started with levetiracetam (dose, frequency and route of administration 
unknown) for seizures. On an unknown date, after one month of levetiracetam treatment patient experienced 
interstinal nephritis, renal failure due to renal tubular disorder and his neurological examination was 
normal. Further examinations revealed hypokalemia (3.1mmol/L) and hypomagnesaemia (0.56mmol/L). Patients other 
relavant tests: hemogram, blood urea nitrogen, creatinine, total cortisol, thyroid function tests, creatinine 
clearance, and renal Doppler ultrasound were normal. On an unknown date, levetiracetam was tapered off and 
treatment with 200mg/day lamotrigine was started. Potassium and magnesium levels returned to normal ranges in 
subsequent tests. Outcome of the events was unknown at the time of report. 
Author's discussion: Hypokalemia, found in the early period in this case, may be an indicator of a recently 
developed renal tubular disorder. This experience indicates that unpredictable side effects of increasingly 
used new antiepileptic drugs should be taken into consideration.
Since Glenmark does not have market authorization for levetiracetam in Turkey; Glenmark product was ruled out 
of consideration in terms of expedited reporting
This report is for a non-Glenmark product; hence is processed only for signal management. It is closed after 
data Entry.</narrativeincludeclinical>
 <senderdiagnosismeddraversion>17.1</senderdiagnosismeddraversion>
 <senderdiagnosis>Renal tubular disorder</senderdiagnosis>
 </summary>
 </patient>
 </safetyreport>